KRT16P2 and malignant glioma: Since all three pathways act through AC020907.1, Y_RNA, TMEM72‐AS1, KRT16P2, DLX6‐AS1, AP002414.1, hsa‐miR‐424, TBPL1, NPAS2, and CRY2, these genes could serve as potential therapeutic targets for malignant glioma.